Albumin-bilirubin score in non-malignant liver and other diseases.

IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY World Journal of Gastroenterology Pub Date : 2024-11-07 DOI:10.3748/wjg.v30.i41.4481
Li-Fan Zhang, Liu-Xiang Chen, Wen-Juan Yang, Bing Hu
{"title":"Albumin-bilirubin score in non-malignant liver and other diseases.","authors":"Li-Fan Zhang, Liu-Xiang Chen, Wen-Juan Yang, Bing Hu","doi":"10.3748/wjg.v30.i41.4481","DOIUrl":null,"url":null,"abstract":"<p><p>The albumin-bilirubin (ALBI) score is derived from albumin and bilirubin levels. Currently, the ALBI score is widely used in various clinical settings. A recent article in the <i>World Journal of Gastroenterology</i> summarized the application of the ALBI score in various non-malignant liver diseases. The ALBI score has a predictive power that is superior or non-inferior to established numerous measures. This may be related to its contiguity, sensitivity, and inclusion of albumin. While we recognize the good results of the ALBI score in a number of diseases, the ALBI score also has limitations. Variation studies for population characteristics and other factors should be performed to validate the performance of ALBI. Further modifications or optimization of ALBI scores should be taken into account.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":"30 41","pages":"4481-4483"},"PeriodicalIF":4.3000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551678/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3748/wjg.v30.i41.4481","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The albumin-bilirubin (ALBI) score is derived from albumin and bilirubin levels. Currently, the ALBI score is widely used in various clinical settings. A recent article in the World Journal of Gastroenterology summarized the application of the ALBI score in various non-malignant liver diseases. The ALBI score has a predictive power that is superior or non-inferior to established numerous measures. This may be related to its contiguity, sensitivity, and inclusion of albumin. While we recognize the good results of the ALBI score in a number of diseases, the ALBI score also has limitations. Variation studies for population characteristics and other factors should be performed to validate the performance of ALBI. Further modifications or optimization of ALBI scores should be taken into account.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非恶性肝病和其他疾病的白蛋白-胆红素评分。
白蛋白胆红素(ALBI)评分是根据白蛋白和胆红素水平得出的。目前,ALBI 评分已广泛应用于各种临床环境。世界胃肠病学杂志》最近发表的一篇文章总结了 ALBI 评分在各种非恶性肝病中的应用。ALBI 评分的预测能力优于或不劣于已有的众多指标。这可能与它的连续性、敏感性和包含白蛋白有关。虽然我们认识到 ALBI 评分在许多疾病中的良好效果,但 ALBI 评分也有其局限性。应针对人群特征和其他因素进行变异研究,以验证 ALBI 的性能。应考虑进一步修改或优化 ALBI 评分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
World Journal of Gastroenterology
World Journal of Gastroenterology 医学-胃肠肝病学
CiteScore
7.80
自引率
4.70%
发文量
464
审稿时长
2.4 months
期刊介绍: The primary aims of the WJG are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in gastroenterology and hepatology.
期刊最新文献
Advances in artificial intelligence for predicting complication risks post-laparoscopic radical gastrectomy for gastric cancer: A significant leap forward. Comprehensive approach to esophageal variceal bleeding: From prevention to treatment. Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function. Improving early diagnosis of multiple endocrine neoplasia type 1 by assessing the gastrointestinal symptoms, hypercalcemia, and elevated serum gastrin. Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1